If you're hunting for the market's next scorching momentum plays, you'll want to buckle up. We're spotlighting 8 stocks that have Wall Street's brightest minds pounding the table as potential homerun hitters.
From innovative disruptors to established giants flexing their dominance, these tickers have analysts scribbling bold new price targets and investors foaming at the mouth over their upside potential. A cup of FOMO is getting passed around - and you'll want a sip before it's drained.
So which potential rockets are making the biggest waves? Here's a rapid-fire look at 8 sizzlers on the verge of blast-off:
Feel the Burn With Celsius (CELH)
In the bourgeoning energy drink space, few names get analysts more fired up than Celsius Holdings. The fitness beverage upstart has muscled its way to a cult-like following, prompting analysts to shower it with Buy ratings and an average $76 price target - a tantalizing 26% upside from current levels. With monster growth projections, CELH is catnip for adrenaline junkies looking to get amped.
NIKE (NKE): The Ultimate Shoe-In?
When it comes to elite sportswear brands, NIKE is the brand to beat. And though detractors gripe about NKE's rich valuation, the shoe titan continues racking up Street-high price targets as it parlays its cultural cachet into financial wizardry. At $106 per share, analysts see Nike stock breaking fresh records with over 20% upside still on the table.
Inspire (INSP) Sparks 100%+ Drool Potential
In the beaten-down medical device realm, Inspire Medical stands out as a diamond in the rough that has the smart moneysSalivating. Focused on innovative sleep apnea solutions, this $231 stock boasts reams of Buy ratings and triple-digit percentage upside potential, per analysts. For those craving lottery ticket-esque upside, few names breed as much drool.
Silicon Valley Billionaires Are Quietly Buying Into What We Call the "Imperium" Boom
![](https://mcusercontent.com/6e7112ee59dfce21b40dd90be/images/07c0a418-6a47-8f3c-1a3b-cec1430848e2.png)
Details here.
![](https://gallery.mailchimp.com/6e7112ee59dfce21b40dd90be/images/5381a560-c43d-4139-8a39-c27df52cf896.png)
Let Ferrari (RACE) Rev Your Engines
Burnish those shoes and grab your finest handkerchief - we're talking luxury Italian automotive royalty here. Though not a beaten-down bargain, Ferrari stock's Street-high $441 price target and elite brand power have investors basking in the gloria. Whether it keeps its pole position is another story, but few names deliver passion investments quite like RACE.
Game-Changing Billion-Dollar Blockbusters Fuel Ionis (IONS) Fire
The biotech sphere is littered with boom-and-bust busts, but Ionis Pharma has carved out a reputation for cold, hard results. Thanks to a trio of potential billion-dollar blockbuster candidates, the $56 price target implies 35% upside as Ionis aims to follow the lead of fellow antisense drug trailblazers. For risk-tolerant biotech buffs, this rocket may just be worth a gander.
For Those Seeking A "Steady Eddie" - Comerica (CMA) and Illumina (ILMN)
If supersonic thrill rides make you nauseous, Bank of Mom-and-Dad Comerica and DNA sequencing cash cow Illumina offer lower-octane momentum potential. These stalwarts may lack the lottery-esque frenzy of their racier counterparts, but their sturdy Buy ratings and 15-20% upside projections appeal to those preferring more modest excitement levels.
And for dessert, the "I Can't Believe It's Not Meme Stock" Wildcard - Intra-Cellular (ITCI)
Given the buzz around trippy new therapies, it's no surprise Intra-Cellular Therapies has captured imaginations. With a stellar $96 price target implying nearly 50% upside, ITCI has all the makings of a meme-tastic frenzy play: a cult-y aura, novel drugs, and a passionate Reddit following. The stock may be up 30% this month, but traders warn the party is only just getting started for this schizophrenia/bipolar disruptor.
Between disruptors, cash cows, and that final meme cherry on top, this freshly baked batch of tickers has all the ingredients to satisfy investors' cravings. Some will skyrocket, others may flame out spectacularly. But one thing is certain - these 8 Wall Street darlings won't be slumbering for long.